Sökresultat

Filtyp

Din sökning på "*" gav 551143 sökträffar

Äntligen tid för iT1D-studien!

Spänn fast säkerhetsbältena för nu kör vi igång! En ny uppföljningsstudie har startat och vi hoppas att många hänger med på resan. iT1D är en observationsstudie där man vill ta reda på mer information om typ 1-diabetes och faktorer som kan påverka insjuknandet. Huvudsyftet är att upptäcka sjukdomen i tidigt skede och förhindra ett allvarligt insjuknande. De som kan delta i studien är:Barn 0-10 år

https://www.gppad.lu.se/artikel/antligen-tid-it1d-studien - 2025-12-27

IDAC är igång

I vår nyaste studie, IDAC, undersöks om intensiv kost-och fysisk aktivitetsrådgivning under de två första levnadsåren minskar frekvensen av typ 1-diabetesrelaterade autoantikroppar och om det påverkar barnets insulinproducerande celler.Barn med en medelhög genetisk risk för typ 1-diabetes (7-10%) kan delta i studien.Läs mer här om IDAC.

https://www.gppad.lu.se/artikel/idac-ar-igang - 2025-12-27

Drop-in

Nu har vår mottagning i Kristianstad stängt och deltagare som tidigare kommit på besök i Kristianstad är välkomna till Malmö.All provtagning för ASTR1D efter födseln sker numera i Malmö. Vi har drop-in för ASTR1D provtagning på tisdagar kl 10:00-12:00. Vi finns på CRC, adress Jan Waldenströmsgata 35, i ett hus på sjukhusområdet bredvid KK.Länk till karta (nytt fönster) 

https://www.gppad.lu.se/artikel/drop - 2025-12-27

Världsdiabetesdagen 2025

Den 14 november är det Världsdiabetesdagen. Det är en dag då diabetes uppmärksammas över hela världen. Detta år är temat för dagen i Skåne, Hälsa och Välbefinnande vid Diabetes.I Malmö anordnas en eftermiddag med föreläsningar och utställningar om forskning och annat relaterat till diabetes torsdagen den 13 november. Alla är varmt välkomna!Programmet hittar ni här (nytt fönster)

https://www.gppad.lu.se/artikel/varldsdiabetesdagen-2025 - 2025-12-27

Nya forskningssjuksköterskor

Vi har två nya sjuksköterskor på vår mottagning, Betty och Filippa. Betty jobbar i studierna IDAC, PreCise och GRaIn och Filippa jobbar i GRaIn och PreCise follow-up. Båda två har erfarenhet av att jobba med barn i olika åldrar och ser fram emot att träffa er.

https://www.gppad.lu.se/node/398 - 2025-12-27

Kolla brevlådan!

Alla familjer som varit med i POInT borde få brev denna veckan. I brevet står det om barnet fått oralt insulin eller placebo i studien. Idag den 12 november har studiens resultat publicerats i den vetenskapliga tidningen Lancet, här är en länk till artikeln i PDF format (nytt fönster). Ett pressmeddelande har publicerats av Lunds universitet, det hittar ni här (nytt fönster).  

https://www.gppad.lu.se/artikel/kolla-brevladan - 2025-12-27

From molecule to patient – Six promising projects to advance Parkinson's research

What role does an inflammatory protein have in disease development? Which neuronal circuits cause different symptoms? How may diabetes affect Parkinson’s disease? Can motor signs be identifies early in individuals at risk for the disease? And how should patients in very advanced disease stages be treated to maintain their quality of life? These questions may soon have answers thanks to several ong

https://www.multipark.lu.se/article/molecule-patient-six-promising-projects-advance-parkinsons-research - 2025-12-27

A new reliable blood marker reveals the extent of Alzheimer’s pathology in the brain

Researchers at Lund University and Washington University have identified a blood marker that reflects the amount of Alzheimer’s pathology in the brain. This discovery may play a key role in determining who is most likely to benefit from the new Alzheimer’s drugs. In brief:A newly discovered blood marker, MTBR-tau243, can reveal how much Alzheimer’s disease pathology is present in the brain. The hi

https://www.multipark.lu.se/article/new-reliable-blood-marker-reveals-extent-alzheimers-pathology-brain - 2025-12-27

More opportunities to test for Alzheimer’s using new analytical method

A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led by Lund University in Sweden. “This is a major step in bringing simple blood tests for Alzheimer’s disease into the healthcare system globally,” say the researchers behind the study. In brief:The blood-based marker (P-tau217) may start to change several years before the onset of Al

https://www.multipark.lu.se/article/more-opportunities-test-alzheimers-using-new-analytical-method - 2025-12-27

Meet Our Scientists Podcast: Gesine Paul-Visse about the brain’s frontline

Meet our scientist Gesine Paul-Visse to learn what happens at the interface where the brain and the body meet: the blood-brain barrier. Here, a very specialized cell, the pericyte, protects the brain and responds strongly to disease. Gesine Paul-Visse leads Translational Neurology, one of MultiPark’s research groups. As both a neurologist and a researcher, she has focused on neurodegeneration for

https://www.multipark.lu.se/article/meet-our-scientists-podcast-gesine-paul-visse-about-brains-frontline - 2025-12-27

Protein mismanagement in brain's control center fuels early symptoms in neurodegenerative diseases

Researchers at MultiPark have uncovered in mice how the protein TDP-43, known for its role in several neurodegenerative diseases, disrupts the hypothalamus, the brain’s key center for metabolic control. Their study sheds new light on the role of TDP-43 in metabolic and psychiatric symptoms shared across frontotemporal dementia, Huntington’s disease, and ALS – findings that could support the develo

https://www.multipark.lu.se/article/protein-mismanagement-brains-control-center-fuels-early-symptoms-neurodegenerative-diseases - 2025-12-27

Brain activation pattern behind impulsivity in Parkinson’s treatment discovered

An experimental study from Lund University reveals for the first time that different Parkinson’s medications affect brain activity in distinct ways. This could explain why some patients develop impulsive and compulsive behaviors as a result of their treatment. The findings have been published in NPJ Parkinson’s Disease. Upon receiving treatment for their motor symptoms, many patients with Parkinso

https://www.multipark.lu.se/article/brain-activation-pattern-behind-impulsivity-parkinsons-treatment-discovered - 2025-12-27

Meet Our Scientists Podcast: Niklas Mattsson-Carlgren about biomarkers and the future of Alzheimer’s

Meet our scientist, Dr. Niklas Mattsson-Carlgren! He explains why studying biomarkers is essential to advancing Alzheimer’s research. Niklas Mattsson-Carlgren is part of the Clinical Memory Research group, a leading centre in the development and evaluation of novel biomarkers for Alzheimer’s disease. In this podcast episode, he discusses why biomarker research is key not only to detecting but also

https://www.multipark.lu.se/article/meet-our-scientists-podcast-niklas-mattsson-carlgren-about-biomarkers-and-future-alzheimers - 2025-12-27

Alzheimer’s awareness: Five research projects shaping the future of understanding, diagnosis and care

With over 15 research groups dedicated to Alzheimer’s disease research, MultiPark’s goal is to understand the origins of the disease, develop early diagnostics, and improve treatments. The multidisciplinary approach sheds light on the disease from several angles, bridging basic research with clinical investigations. Here are five projects. September is World Alzheimer’s Month. Globally, around 40

https://www.multipark.lu.se/article/alzheimers-awareness-five-research-projects-shaping-future-understanding-diagnosis-and-care - 2025-12-27

Why repetitive DNA matters for human brain evolution and disease

For decades, large stretches of human DNA were dismissed as ‘junk’ and considered to serve no real purpose. In a new study in Cell Genomics, researchers at Lund University in Sweden show that the repetitive part of the human genome plays an active role during early brain development and may also be relevant for understanding brain diseases. DNA carries the complete set of instructions an organism

https://www.multipark.lu.se/article/why-repetitive-dna-matters-human-brain-evolution-and-disease - 2025-12-27